Hypothyroidism induced by phenytoin and gabapentin A Case Report

被引:8
作者
Miyake, Zenshi [1 ]
Ishii, Kazuhiro [1 ]
Tamaoka, Akira [1 ]
机构
[1] Univ Tsukuba, Fac Med, Div Clin Med, Dept Neurol, Tennodai 1-1-1, Tsukuba, Ibaraki 3058575, Japan
关键词
antiepileptic drug; case report; gabapentin; hypothyroidism; phenytoin; ANTIEPILEPTIC DRUGS; THYROID-HORMONE; SUBCLINICAL HYPOTHYROIDISM; CARBAMAZEPINE; OXCARBAZEPINE; VALPROATE; EPILEPSY; CHILDREN; THERAPY; GABA;
D O I
10.1097/MD.0000000000012938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Antiepileptic drugs (AEDs) are one of the causative drugs of drug-induced hypothyroidism. In most cases, AED-induced hypothyroidism is subclinical and indicated only by abnormalities of free thyroxine (T4) and/or thyroid-stimulating hormone (TSH) levels. Severe symptomatic hypothyroidism following AEDs is rarely reported in the literature. Patient concerns: A 75-year-old man experienced neurologic symptoms including memory impairment, ataxic gait, sensory polyneuropathy and myopathy, lethargy, and edema of the face and lower extremities. He had been administered phenytoin and gabapentin for the treatment of symptomatic traumatic epilepsy 8 years before. Diagnoses: The patient had low free T4 (0.21 ng/dL) and high TSH (113.2 mu IU/mL), which indicated hypothyroidism. Negative thyroid-related autoantibody tests and the lack of goiter excluded the possibility of Hashimoto disease. Phenytoin and/or gabapentin were strongly suspected as causing his hypothyroidism. Intervention: The patient was treated with replacement therapy (levothyroxine 25 mu g/day). Outcomes: His symptoms markedly and promptly improved alongside continued antiepileptic therapy. Lessons: In this case, the patient's hypothyroidism was assumed to result from different mechanisms of the 2 AEDs leading to thyroid hormone reduction. AEDs can not only cause asymptomatic thyroid hormone abnormalities but also clinically observable hypothyroidism. Therefore, clinicians should be aware of the association between anticonvulsants and symptomatic hypothyroidism.
引用
收藏
页数:3
相关论文
共 21 条
[1]   Thyroid Hormone Levels in Children Receiving Carbamazepine or Valproate [J].
Aggarwal, Anju ;
Rastogi, Neha ;
Mittal, Hema ;
Chillar, Neelam ;
Patil, Rahul .
PEDIATRIC NEUROLOGY, 2011, 45 (03) :159-162
[2]   A mechanistic approach to antiepileptic drug interactions [J].
Anderson, GD .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (05) :554-563
[3]   Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction [J].
Benedetti, MS ;
Whomsley, R ;
Baltes, E ;
Tonner, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) :863-872
[4]   Hypothyroidism [J].
Chaker, Layal ;
Bianco, Antonio C. ;
Jonklaas, Jacqueline ;
Peeters, Robin P. .
LANCET, 2017, 390 (10101) :1550-1562
[5]   CHANGES IN CIRCULATING THYROID-HORMONES DURING SHORT-TERM HEPATIC ENZYME-INDUCTION WITH CARBAMAZEPINE [J].
CONNELL, JMC ;
RAPEPORT, WG ;
GORDON, S ;
BRODIE, MJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (04) :453-456
[6]   PHENYTOIN AND THYROID-HORMONE ACTION [J].
FRANKLYN, JA ;
DAVIS, JRE ;
RAMSDEN, DB ;
SHEPPARD, MC .
JOURNAL OF ENDOCRINOLOGY, 1985, 104 (02) :201-204
[7]   The effect of antiepileptic drugs on thyroid hormonal function: causes and implications [J].
Hamed, Sherifa Ahmed .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (06) :741-750
[8]   Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy [J].
Isojärvi, JIT ;
Turkka, J ;
Pakarinen, AJ ;
Kotila, M ;
Rättyä, J ;
Myllylä, VV .
EPILEPSIA, 2001, 42 (07) :930-934
[9]   Subclinical Hypothyroidism during Valproic Acid Therapy in Children and Adolescents with Epilepsy [J].
Kim, Se Hee ;
Chung, Hye Rim ;
Kim, Seung Hyo ;
Kim, Hunmin ;
Lim, Byung Chan ;
Chae, Jong Hee ;
Kim, Ki Joong ;
Hwang, Yong Seung ;
Hwang, Hee .
NEUROPEDIATRICS, 2012, 43 (03) :135-139
[10]   Use of antiepileptic drugs and risk of hypothyroidism [J].
Lai, Edward Chia-Cheng ;
Yang, Yea-Huei Kao ;
Lin, Swu-Jane ;
Hsieh, Cheng-Yang .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (10) :1071-1079